Share on StockTwits

Analysts at Aegis upped their price objective on shares of PharmAthene (NYSE:PIP) to $6.00 in a research report issued to clients and investors on Monday. Aegis’ price target would indicate a potential upside of 377.33% from the stock’s previous close.

PharmAthene (NYSE:PIP) traded up 41.21% during mid-day trading on Monday, hitting $1.775. 3,221,009 shares of the company’s stock traded hands. PharmAthene has a one year low of $1.19 and a one year high of $2.42. The stock has a 50-day moving average of $1.37 and a 200-day moving average of $1.6. The company’s market cap is $98.6 million.

PharmAthene (NYSE:PIP) last released its earnings data on Monday, August 4th. The company reported ($0.01) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.06) by $0.05. On average, analysts predict that PharmAthene will post $-0.22 earnings per share for the current fiscal year.

PharmAthene, Inc is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.